ID   C11B2_HUMAN             Reviewed;         503 AA.
AC   P19099; B0ZBE4; Q16726;
DT   01-NOV-1990, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 3.
DT   10-MAY-2017, entry version 187.
DE   RecName: Full=Cytochrome P450 11B2, mitochondrial;
DE   AltName: Full=Aldosterone synthase;
DE            Short=ALDOS;
DE            EC=1.14.15.4;
DE            EC=1.14.15.5;
DE   AltName: Full=Aldosterone-synthesizing enzyme;
DE   AltName: Full=CYPXIB2;
DE   AltName: Full=Cytochrome P-450Aldo;
DE   AltName: Full=Cytochrome P-450C18;
DE   AltName: Full=Steroid 18-hydroxylase;
DE   Flags: Precursor;
GN   Name=CYP11B2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=2592361;
RA   Mornet E., Dupont J., Vitek A., White P.C.;
RT   "Characterization of two genes encoding human steroid 11 beta-
RT   hydroxylase (P-450(11) beta).";
RL   J. Biol. Chem. 264:20961-20967(1989).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Adrenal gland;
RX   PubMed=2256920; DOI=10.1016/S0006-291X(05)81058-7;
RA   Kawamoto T., Mitsuuchi Y., Ohnishi T., Ichikawa Y., Yokoyama Y.,
RA   Sumimoto H., Toda K., Miyahara K., Kuribayashi I., Nakao K.,
RA   Hosoda K., Yamamoto Y., Imura H., Shizuta Y.;
RT   "Cloning and expression of a cDNA for human cytochrome P-450aldo as
RT   related to primary aldosteronism.";
RL   Biochem. Biophys. Res. Commun. 173:309-316(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   TISSUE=Blood;
RA   Kawamoto T., Miyahara K., Mitsuuchi Y., Ulick S., Shizuta Y.;
RL   Submitted (JUN-1994) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 34-503 IN COMPLEXES WITH
RP   HEME; DESOXYCORTICOSTERONE AND SYNTHETIC INHIBITOR FADROZOLE,
RP   CATALYTIC ACTIVITY, COFACTOR, AND FUNCTION.
RX   PubMed=23322723; DOI=10.1210/me.2012-1287;
RA   Strushkevich N., Gilep A.A., Shen L., Arrowsmith C.H., Edwards A.M.,
RA   Usanov S.A., Park H.W.;
RT   "Structural insights into aldosterone synthase substrate specificity
RT   and targeted inhibition.";
RL   Mol. Endocrinol. 27:315-324(2013).
RN   [7]
RP   VARIANTS CMO-2 DEFICIENCY TRP-181 AND ALA-386.
RX   PubMed=1594605; DOI=10.1073/pnas.89.11.4996;
RA   Pascoe L., Curnow K.M., Slutsker L., Roesler A., White P.C.;
RT   "Mutations in the human CYP11B2 (aldosterone synthase) gene causing
RT   corticosterone methyloxidase II deficiency.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:4996-5000(1992).
RN   [8]
RP   VARIANTS CMO-2 DEFICIENCY TRP-181 AND ALA-386.
RX   PubMed=1346492; DOI=10.1016/0006-291X(92)91827-D;
RA   Mitsuuchi Y., Kawamoto T., Naiki Y., Miyahara K., Toda K.,
RA   Kuribayashi I., Orii T., Yasuda K., Miura K., Nakao K., Imura H.,
RA   Ulick S., Shizuta Y.;
RT   "Congenitally defective aldosterone biosynthesis in humans: the
RT   involvement of point mutations of the P-450C18 gene (CYP11B2) in CMO
RT   II deficient patients.";
RL   Biochem. Biophys. Res. Commun. 182:974-979(1992).
RN   [9]
RP   ERRATUM.
RA   Mitsuuchi Y., Kawamoto T., Naiki Y., Miyahara K., Toda K.,
RA   Kuribayashi I., Orii T., Yasuda K., Miura K., Nakao K., Imura H.,
RA   Ulick S., Shizuta Y.;
RL   Biochem. Biophys. Res. Commun. 184:1529-1530(1992).
RN   [10]
RP   DISEASE.
RX   PubMed=8439335; DOI=10.1006/bbrc.1993.1128;
RA   Mitsuuchi Y., Kawamoto T., Miyahara K., Ulick S., Morton D.H.,
RA   Naiki Y., Kuribayashi I., Toda K., Hara T., Orii T., Yasuda K.,
RA   Miura K., Yamamoto Y., Imura H., Shizuta Y.;
RT   "Congenitally defective aldosterone biosynthesis in humans:
RT   inactivation of the P-450(C18) gene (CYP11B2) due to nucleotide
RT   deletion in CMO I deficient patients.";
RL   Biochem. Biophys. Res. Commun. 190:864-869(1993).
RN   [11]
RP   VARIANT CMO-1 DEFICIENCY PRO-461.
RX   PubMed=9177280; DOI=10.1006/bbrc.1997.6651;
RA   Nomoto S., Massa G., Mitani F., Ishimura Y., Miyahara K., Toda K.,
RA   Nagano I., Yamashiro T., Ogoshi S., Fukata J., Onishi S.,
RA   Hashimoto K., Doi Y., Imura H., Shizuta Y.;
RT   "CMO I deficiency caused by a point mutation in exon 8 of the human
RT   CYP11B2 gene encoding steroid 18-hydroxylase (P450C18).";
RL   Biochem. Biophys. Res. Commun. 234:382-385(1997).
RN   [12]
RP   VARIANT CMO-2 DEFICIENCY ILE-185.
RX   PubMed=9625333; DOI=10.1007/s004310050833;
RA   Peter M., Buenger K., Solyom J., Sippell W.G.;
RT   "Mutation THR-185 ILE is associated with corticosterone methyl oxidase
RT   deficiency type II.";
RL   Eur. J. Pediatr. 157:378-381(1998).
RN   [13]
RP   VARIANTS CMO-2 DEFICIENCY ASP-198 AND ALA-386.
RX   PubMed=9814506; DOI=10.1210/jcem.83.11.5258;
RA   Portrat-Doyen S., Tourniaire J., Richard O., Mulatero P.,
RA   Aupetit-Faisant B., Curnow K.M., Pascoe L., Morel Y.;
RT   "Isolated aldosterone synthase deficiency caused by simultaneous E198D
RT   and V386A mutations in the CYP11B2 gene.";
RL   J. Clin. Endocrinol. Metab. 83:4156-4161(1998).
RN   [14]
RP   VARIANT ARG-173.
RX   PubMed=9931115; DOI=10.1161/01.HYP.33.1.266;
RA   Tamaki S., Iwai N., Tsujita Y., Kinoshita M.;
RT   "Genetic polymorphism of CYP11B2 gene and hypertension in Japanese.";
RL   Hypertension 33:266-270(1999).
RN   [15]
RP   VARIANTS THR-29; GLN-30; ARG-173; THR-248; SER-281; THR-339; ALA-386
RP   AND SER-435.
RX   PubMed=10391209; DOI=10.1038/10290;
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RT   "Characterization of single-nucleotide polymorphisms in coding regions
RT   of human genes.";
RL   Nat. Genet. 22:231-238(1999).
RN   [16]
RP   ERRATUM.
RA   Cargill M., Altshuler D., Ireland J., Sklar P., Ardlie K., Patil N.,
RA   Shaw N., Lane C.R., Lim E.P., Kalyanaraman N., Nemesh J., Ziaugra L.,
RA   Friedland L., Rolfe A., Warrington J., Lipshutz R., Daley G.Q.,
RA   Lander E.S.;
RL   Nat. Genet. 23:373-373(1999).
RN   [17]
RP   VARIANTS ARG-173; THR-248; SER-281; THR-339; ALA-386 AND SER-435.
RX   PubMed=10391210; DOI=10.1038/10297;
RA   Halushka M.K., Fan J.-B., Bentley K., Hsie L., Shen N., Weder A.,
RA   Cooper R., Lipshutz R., Chakravarti A.;
RT   "Patterns of single-nucleotide polymorphisms in candidate genes for
RT   blood-pressure homeostasis.";
RL   Nat. Genet. 22:239-247(1999).
RN   [18]
RP   VARIANT CMO-1 DEFICIENCY ARG-LEU-140 INS.
RX   PubMed=11238478; DOI=10.1210/jcem.86.3.7326;
RA   Kayes-Wandover K.M., Schindler R.E.L., Taylor H.C., White P.C.;
RT   "Type 1 aldosterone synthase deficiency presenting in a middle-aged
RT   man.";
RL   J. Clin. Endocrinol. Metab. 86:1008-1012(2001).
RN   [19]
RP   VARIANTS CMO-2 DEFICIENCY ILE-185 AND ALA-498.
RX   PubMed=12788848; DOI=10.1210/jc.2003-030353;
RA   Dunlop F.M., Crock P.A., Montalto J., Funder J.W., Curnow K.M.;
RT   "A compound heterozygote case of type II aldosterone synthase
RT   deficiency.";
RL   J. Clin. Endocrinol. Metab. 88:2518-2526(2003).
CC   -!- FUNCTION: Preferentially catalyzes the conversion of 11-
CC       deoxycorticosterone to aldosterone via corticosterone and 18-
CC       hydroxycorticosterone. {ECO:0000269|PubMed:23322723}.
CC   -!- CATALYTIC ACTIVITY: A steroid + 2 reduced adrenodoxin + O(2) + 2
CC       H(+) = an 11-beta- hydroxysteroid + 2 oxidized adrenodoxin +
CC       H(2)O. {ECO:0000269|PubMed:23322723}.
CC   -!- CATALYTIC ACTIVITY: Corticosterone + 2 reduced adrenodoxin + O(2)
CC       + 2 H(+) = 18-hydroxycorticosterone + 2 oxidized adrenodoxin +
CC       H(2)O. {ECO:0000269|PubMed:23322723}.
CC   -!- COFACTOR:
CC       Name=heme; Xref=ChEBI:CHEBI:30413;
CC         Evidence={ECO:0000269|PubMed:23322723};
CC   -!- SUBCELLULAR LOCATION: Mitochondrion membrane.
CC   -!- DISEASE: Corticosterone methyloxidase 1 deficiency (CMO-1
CC       deficiency) [MIM:203400]: Autosomal recessive disorder of
CC       aldosterone biosynthesis. There are two biochemically different
CC       forms of selective aldosterone deficiency be termed corticosterone
CC       methyloxidase (CMO) deficiency type 1 and type 2. In CMO-1
CC       deficiency, aldosterone is undetectable in plasma, while its
CC       immediate precursor, 18-hydroxycorticosterone, is low or normal.
CC       {ECO:0000269|PubMed:11238478, ECO:0000269|PubMed:9177280}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Corticosterone methyloxidase 2 deficiency (CMO-2
CC       deficiency) [MIM:610600]: Autosomal recessive disorder of
CC       aldosterone biosynthesis. In CMO-2 deficiency, aldosterone can be
CC       low or normal, but at the expense of increased secretion of 18-
CC       hydroxycorticosterone. Consequently, patients have a greatly
CC       increased ratio of 18-hydroxycorticosterone to aldosterone and a
CC       low ratio of corticosterone to 18-hydroxycorticosterone in serum.
CC       {ECO:0000269|PubMed:12788848, ECO:0000269|PubMed:1346492,
CC       ECO:0000269|PubMed:1594605, ECO:0000269|PubMed:9625333,
CC       ECO:0000269|PubMed:9814506}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Hyperaldosteronism, familial, 1 (HALD1) [MIM:103900]: A
CC       disorder characterized by hypertension, variable
CC       hyperaldosteronism, and abnormal adrenal steroid production,
CC       including 18-oxocortisol and 18-hydroxycortisol. There is
CC       significant phenotypic heterogeneity, and some individuals never
CC       develop hypertension. Note=The disease is caused by mutations
CC       affecting the gene represented in this entry. The molecular defect
CC       causing hyperaldosteronism familial 1 is an anti-Lepore-type
CC       fusion of the CYP11B1 and CYP11B2 genes. The hybrid gene has the
CC       promoting part of CYP11B1, ACTH-sensitive, and the coding part of
CC       CYP11B2.
CC   -!- SIMILARITY: Belongs to the cytochrome P450 family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=CYP11B2 entry;
CC       URL="https://en.wikipedia.org/wiki/CYP11B2";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M32881; AAA35741.1; -; Genomic_DNA.
DR   EMBL; M32864; AAA35741.1; JOINED; Genomic_DNA.
DR   EMBL; M32880; AAA35741.1; JOINED; Genomic_DNA.
DR   EMBL; X54741; CAA38539.1; -; mRNA.
DR   EMBL; D13752; BAA02899.1; -; Genomic_DNA.
DR   EMBL; EU326306; ACA05912.1; -; Genomic_DNA.
DR   EMBL; CH471162; EAW82292.1; -; Genomic_DNA.
DR   CCDS; CCDS6393.1; -.
DR   PIR; B34181; B34181.
DR   RefSeq; NP_000489.3; NM_000498.3.
DR   UniGene; Hs.632054; -.
DR   PDB; 4DVQ; X-ray; 2.49 A; A/B/C/D/E/F/G/H/I/J/K/L=34-503.
DR   PDB; 4FDH; X-ray; 2.71 A; A/B/C/D/E/F/G/H/I/J/K/L=34-503.
DR   PDB; 4ZGX; X-ray; 3.20 A; A/B/C/D/E/F/G/H/I/J/K/L=28-503.
DR   PDBsum; 4DVQ; -.
DR   PDBsum; 4FDH; -.
DR   PDBsum; 4ZGX; -.
DR   ProteinModelPortal; P19099; -.
DR   SMR; P19099; -.
DR   BioGrid; 107957; 1.
DR   STRING; 9606.ENSP00000325822; -.
DR   BindingDB; P19099; -.
DR   ChEMBL; CHEMBL2722; -.
DR   DrugBank; DB04630; Aldosterone.
DR   DrugBank; DB00700; Eplerenone.
DR   DrugBank; DB00292; Etomidate.
DR   DrugBank; DB00741; Hydrocortisone.
DR   DrugBank; DB01233; Metoclopramide.
DR   DrugBank; DB01011; Metyrapone.
DR   DrugBank; DB01388; Mibefradil.
DR   DrugBank; DB00421; Spironolactone.
DR   GuidetoPHARMACOLOGY; 1360; -.
DR   SwissLipids; SLP:000001198; -.
DR   iPTMnet; P19099; -.
DR   PhosphoSitePlus; P19099; -.
DR   BioMuta; CYP11B2; -.
DR   DMDM; 3041666; -.
DR   PaxDb; P19099; -.
DR   PeptideAtlas; P19099; -.
DR   PRIDE; P19099; -.
DR   DNASU; 1585; -.
DR   Ensembl; ENST00000323110; ENSP00000325822; ENSG00000179142.
DR   GeneID; 1585; -.
DR   KEGG; hsa:1585; -.
DR   UCSC; uc003yxk.1; human.
DR   CTD; 1585; -.
DR   DisGeNET; 1585; -.
DR   GeneCards; CYP11B2; -.
DR   H-InvDB; HIX0034383; -.
DR   HGNC; HGNC:2592; CYP11B2.
DR   HPA; HPA049171; -.
DR   HPA; HPA056348; -.
DR   HPA; HPA057752; -.
DR   MalaCards; CYP11B2; -.
DR   MIM; 103900; phenotype.
DR   MIM; 124080; gene.
DR   MIM; 203400; phenotype.
DR   MIM; 610600; phenotype.
DR   neXtProt; NX_P19099; -.
DR   OpenTargets; ENSG00000179142; -.
DR   Orphanet; 403; Familial hyperaldosteronism type I.
DR   Orphanet; 99763; Familial hyperreninemic hypoaldosteronism type 1.
DR   PharmGKB; PA134; -.
DR   eggNOG; KOG0159; Eukaryota.
DR   eggNOG; COG2124; LUCA.
DR   GeneTree; ENSGT00760000119243; -.
DR   HOGENOM; HOG000013161; -.
DR   HOVERGEN; HBG051098; -.
DR   InParanoid; P19099; -.
DR   KO; K07433; -.
DR   OMA; PFEAMPQ; -.
DR   OrthoDB; EOG091G0B8F; -.
DR   PhylomeDB; P19099; -.
DR   TreeFam; TF105094; -.
DR   BioCyc; MetaCyc:HS11355-MONOMER; -.
DR   BRENDA; 1.14.15.4; 2681.
DR   Reactome; R-HSA-193993; Mineralocorticoid biosynthesis.
DR   Reactome; R-HSA-194002; Glucocorticoid biosynthesis.
DR   Reactome; R-HSA-211976; Endogenous sterols.
DR   GeneWiki; Aldosterone_synthase; -.
DR   GenomeRNAi; 1585; -.
DR   PRO; PR:P19099; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000179142; -.
DR   CleanEx; HS_CYP11B2; -.
DR   Genevisible; P19099; HS.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0047783; F:corticosterone 18-monooxygenase activity; IBA:GO_Central.
DR   GO; GO:0020037; F:heme binding; IDA:UniProtKB.
DR   GO; GO:0005506; F:iron ion binding; IEA:InterPro.
DR   GO; GO:0004507; F:steroid 11-beta-monooxygenase activity; IDA:UniProtKB.
DR   GO; GO:0008395; F:steroid hydroxylase activity; TAS:Reactome.
DR   GO; GO:0032342; P:aldosterone biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006700; P:C21-steroid hormone biosynthetic process; IDA:BHF-UCL.
DR   GO; GO:0032870; P:cellular response to hormone stimulus; IEP:UniProtKB.
DR   GO; GO:0035865; P:cellular response to potassium ion; IEP:UniProtKB.
DR   GO; GO:0034651; P:cortisol biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0006705; P:mineralocorticoid biosynthetic process; TAS:Reactome.
DR   GO; GO:0055075; P:potassium ion homeostasis; IMP:BHF-UCL.
DR   GO; GO:0002017; P:regulation of blood volume by renal aldosterone; IMP:BHF-UCL.
DR   GO; GO:0003091; P:renal water homeostasis; IC:BHF-UCL.
DR   GO; GO:0055078; P:sodium ion homeostasis; IMP:BHF-UCL.
DR   GO; GO:0016125; P:sterol metabolic process; TAS:Reactome.
DR   InterPro; IPR001128; Cyt_P450.
DR   InterPro; IPR017972; Cyt_P450_CS.
DR   InterPro; IPR002399; Cyt_P450_mitochondrial.
DR   Pfam; PF00067; p450; 1.
DR   PRINTS; PR00408; MITP450.
DR   PRINTS; PR00385; P450.
DR   SUPFAM; SSF48264; SSF48264; 1.
DR   PROSITE; PS00086; CYTOCHROME_P450; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disease mutation; Heme; Iron;
KW   Lipid metabolism; Membrane; Metal-binding; Mitochondrion;
KW   Monooxygenase; Oxidoreductase; Polymorphism; Reference proteome;
KW   Steroid metabolism; Steroidogenesis; Transit peptide.
FT   TRANSIT       1     24       Mitochondrion.
FT   CHAIN        25    503       Cytochrome P450 11B2, mitochondrial.
FT                                /FTId=PRO_0000003597.
FT   METAL       450    450       Iron (heme axial ligand).
FT   VARIANT      29     29       A -> T (in dbSNP:rs6438).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014151.
FT   VARIANT      30     30       R -> Q (in dbSNP:rs6441).
FT                                {ECO:0000269|PubMed:10391209}.
FT                                /FTId=VAR_014152.
FT   VARIANT     140    140       N -> NRL (in CMO-1 deficiency; the enzyme
FT                                is inactive).
FT                                /FTId=VAR_018470.
FT   VARIANT     173    173       K -> R (in dbSNP:rs4539).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:9931115}.
FT                                /FTId=VAR_001266.
FT   VARIANT     181    181       R -> W (in CMO-2 deficiency; reduces 18-
FT                                hydroxylase and abolishes 18-oxidase
FT                                activities; leaves 11 beta-hydroxylase
FT                                activity intact; dbSNP:rs28931609).
FT                                {ECO:0000269|PubMed:1346492,
FT                                ECO:0000269|PubMed:1594605}.
FT                                /FTId=VAR_001267.
FT   VARIANT     185    185       T -> I (in CMO-2 deficiency;
FT                                dbSNP:rs121912978).
FT                                {ECO:0000269|PubMed:12788848,
FT                                ECO:0000269|PubMed:9625333}.
FT                                /FTId=VAR_018471.
FT   VARIANT     198    198       E -> D (in CMO-2 deficiency;
FT                                dbSNP:rs104894072).
FT                                {ECO:0000269|PubMed:9814506}.
FT                                /FTId=VAR_001268.
FT   VARIANT     222    222       N -> T (in dbSNP:rs5308).
FT                                /FTId=VAR_014643.
FT   VARIANT     248    248       I -> T (in dbSNP:rs4547).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014153.
FT   VARIANT     281    281       N -> S (in dbSNP:rs4537).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014154.
FT   VARIANT     339    339       I -> T (in dbSNP:rs4544).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014155.
FT   VARIANT     383    383       E -> V (in dbSNP:rs5312).
FT                                /FTId=VAR_014644.
FT   VARIANT     386    386       V -> A (in CMO-2 deficiency; small but
FT                                consistent reduction in the production of
FT                                18-hydroxycorticosterone;
FT                                dbSNP:rs61757294).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210,
FT                                ECO:0000269|PubMed:1346492,
FT                                ECO:0000269|PubMed:1594605,
FT                                ECO:0000269|PubMed:9814506}.
FT                                /FTId=VAR_001269.
FT   VARIANT     403    403       V -> E (in dbSNP:rs5315).
FT                                /FTId=VAR_014645.
FT   VARIANT     435    435       G -> S (in dbSNP:rs4545).
FT                                {ECO:0000269|PubMed:10391209,
FT                                ECO:0000269|PubMed:10391210}.
FT                                /FTId=VAR_014156.
FT   VARIANT     461    461       L -> P (in CMO-1 deficiency; abolishes
FT                                the 18-hydroxylase activity required for
FT                                conversion of 11-deoxycorticosterone to
FT                                aldosterone; dbSNP:rs72554627).
FT                                {ECO:0000269|PubMed:9177280}.
FT                                /FTId=VAR_018472.
FT   VARIANT     487    487       F -> V (in dbSNP:rs5317).
FT                                /FTId=VAR_014646.
FT   VARIANT     498    498       T -> A (in CMO-2 deficiency;
FT                                dbSNP:rs72554626).
FT                                {ECO:0000269|PubMed:12788848}.
FT                                /FTId=VAR_018473.
FT   CONFLICT     17     17       S -> C (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   CONFLICT     55     55       I -> M (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   CONFLICT    119    119       Y -> I (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   CONFLICT    249    249       S -> R (in Ref. 2; CAA38539).
FT                                {ECO:0000305}.
FT   CONFLICT    342    342       Q -> K (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   CONFLICT    438    438       F -> L (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   CONFLICT    470    470       H -> R (in Ref. 1; AAA35741).
FT                                {ECO:0000305}.
FT   HELIX        38     40       {ECO:0000244|PDB:4DVQ}.
FT   HELIX        48     58       {ECO:0000244|PDB:4DVQ}.
FT   HELIX        64     75       {ECO:0000244|PDB:4DVQ}.
FT   STRAND       77     80       {ECO:0000244|PDB:4DVQ}.
FT   STRAND       84     86       {ECO:0000244|PDB:4DVQ}.
FT   STRAND       88     91       {ECO:0000244|PDB:4DVQ}.
FT   HELIX        94    103       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       114    123       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       129    131       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       134    142       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       145    148       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       151    178       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      182    186       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       189    205       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      212    214       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       218    238       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       242    248       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       250    280       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       289    296       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       301    313       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       317    332       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       334    353       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       355    357       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       358    361       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       363    375       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      381    385       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      390    392       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      395    397       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      402    406       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       407    410       {ECO:0000244|PDB:4DVQ}.
FT   TURN        414    416       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      417    419       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       427    430       {ECO:0000244|PDB:4DVQ}.
FT   HELIX       446    448       {ECO:0000244|PDB:4FDH}.
FT   HELIX       453    470       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      471    474       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      483    493       {ECO:0000244|PDB:4DVQ}.
FT   STRAND      497    501       {ECO:0000244|PDB:4DVQ}.
SQ   SEQUENCE   503 AA;  57560 MW;  42BA671704CEE35D CRC64;
     MALRAKAEVC VAAPWLSLQR ARALGTRAAR APRTVLPFEA MPQHPGNRWL RLLQIWREQG
     YEHLHLEMHQ TFQELGPIFR YNLGGPRMVC VMLPEDVEKL QQVDSLHPCR MILEPWVAYR
     QHRGHKCGVF LLNGPEWRFN RLRLNPDVLS PKAVQRFLPM VDAVARDFSQ ALKKKVLQNA
     RGSLTLDVQP SIFHYTIEAS NLALFGERLG LVGHSPSSAS LNFLHALEVM FKSTVQLMFM
     PRSLSRWISP KVWKEHFEAW DCIFQYGDNC IQKIYQELAF NRPQHYTGIV AELLLKAELS
     LEAIKANSME LTAGSVDTTA FPLLMTLFEL ARNPDVQQIL RQESLAAAAS ISEHPQKATT
     ELPLLRAALK ETLRLYPVGL FLERVVSSDL VLQNYHIPAG TLVQVFLYSL GRNAALFPRP
     ERYNPQRWLD IRGSGRNFHH VPFGFGMRQC LGRRLAEAEM LLLLHHVLKH FLVETLTQED
     IKMVYSFILR PGTSPLLTFR AIN
//
